Toth Financial Advisory Corp boosted its position in Amgen, Inc. (NASDAQ:AMGN) by 4.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,510 shares of the medical research company’s stock after buying an additional 526 shares during the quarter. Toth Financial Advisory Corp’s holdings in Amgen were worth $2,490,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also recently added to or reduced their stakes in the business. Northern Trust Corp grew its position in shares of Amgen by 4.7% in the fourth quarter. Northern Trust Corp now owns 9,182,050 shares of the medical research company’s stock valued at $1,787,470,000 after purchasing an additional 408,675 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Amgen by 5.8% in the fourth quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock valued at $1,720,250,000 after purchasing an additional 482,760 shares in the last quarter. Norges Bank purchased a new position in shares of Amgen in the fourth quarter valued at $1,283,248,000. Nordea Investment Management AB grew its position in shares of Amgen by 5.0% in the first quarter. Nordea Investment Management AB now owns 4,709,467 shares of the medical research company’s stock valued at $894,700,000 after purchasing an additional 225,485 shares in the last quarter. Finally, Legal & General Group Plc grew its position in shares of Amgen by 5.7% in the fourth quarter. Legal & General Group Plc now owns 3,241,580 shares of the medical research company’s stock valued at $631,039,000 after purchasing an additional 174,360 shares in the last quarter. 77.26% of the stock is owned by institutional investors and hedge funds.
NASDAQ:AMGN traded down $0.14 during trading hours on Friday, hitting $173.97. 1,397,205 shares of the company’s stock traded hands, compared to its average volume of 2,410,211. The company has a market cap of $106.24 billion, a price-to-earnings ratio of 12.08, a P/E/G ratio of 2.15 and a beta of 1.16. Amgen, Inc. has a 52 week low of $166.30 and a 52 week high of $210.19. The company has a fifty day moving average of $180.28. The company has a current ratio of 2.77, a quick ratio of 2.53 and a debt-to-equity ratio of 2.71.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, April 30th. The medical research company reported $3.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.45 by $0.11. Amgen had a return on equity of 71.02% and a net margin of 34.00%. The firm had revenue of $5.56 billion during the quarter, compared to analyst estimates of $5.55 billion. During the same quarter in the previous year, the company posted $3.47 earnings per share. The company’s revenue was up .1% compared to the same quarter last year. As a group, equities research analysts anticipate that Amgen, Inc. will post 13.85 earnings per share for the current fiscal year.
In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $175.68, for a total transaction of $351,360.00. Following the completion of the sale, the director now owns 16,219 shares of the company’s stock, valued at $2,849,353.92. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In the last ninety days, insiders have sold 6,000 shares of company stock valued at $1,077,980. Corporate insiders own 0.25% of the company’s stock.
Several equities analysts have recently weighed in on AMGN shares. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Anglo American in a research report on Wednesday, May 15th. Zacks Investment Research upgraded GreenTree Hospitality Group from a “sell” rating to a “hold” rating in a research report on Monday, April 15th. Mizuho set a $21.00 price target on Neon Therapeutics and gave the company a “buy” rating in a research report on Monday, July 1st. Cowen reiterated a “hold” rating and issued a $103.00 price target on shares of United Therapeutics in a research report on Wednesday, May 1st. Finally, Citigroup upgraded Gilead Sciences from a “neutral” rating to a “buy” rating and set a $66.80 price target for the company in a research report on Wednesday, May 22nd. One research analyst has rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the stock. Amgen has an average rating of “Hold” and a consensus target price of $208.10.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Read More: What is systematic risk?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.